Labcorp, a global leader of innovative and comprehensive laboratory services, has officially announced the expansion of its precision oncology portfolio.
According to certain reports, this updated portfolio is likely include, moving forward, new test offerings for solid tumor and hematologic malignancies, along with enhanced biopharma solutions designed to accelerate clinical trials and companion diagnostic development.
Talk about Labcorp’s new offerings on a slightly deeper level, we begin from the availability of new NGS panels for myeloid, lymphoid and pan-heme indications. These new panels arrive on the scene bearing an ability to offer broader genomic coverage and more clinically actionable insights for patients suffering from hematologic malignancies.
The idea here is to help oncologists and pathologists navigate complex diagnoses, and at the same time, guide treatment decisions with greater speed.
Next up, we have the new Rapid AML Panel, which is designed to scale up Labcorp’s comprehensive test menu for acute myeloid leukemia. More on the given panel would reveal how it allows for providers to make timely and informed treatment decisions.
Another detail worth a mention is rooted in expansion of capabilities for OmniSeq® INSIGHT. This translates to how Labcorp’s pan-solid tumor profiling test will now offer homologous recombination deficiency (HRD) testing. Such an offering should come in handy to identify patients with ovarian cancer who are most likely to benefit from targeted therapies, including PARP inhibitors, or who may be eligible for clinical trials.
Joining that would be a collection of enhanced FDA-approved companion diagnostics solutions. These solutions, on their part, include the categorization of HER2-low and HER2-ultralow subtypes in the HER2 IHC test for patients with breast cancer, and the VENTANA® MET (SP44) RxDx Assay for patients with non-squamous non-small cell lung cancer.
Alongside that, Labcorp will also bring to the fore digital pathology advancements for anatomic pathology.
Moving on, as a part of this development, the company is set to expand its line of Plasma solutions. You see, Labcorp will now offer Labcorp Plasma Focus, a solid tumor liquid biopsy test. The stated test provides a rather interesting follow-up to recent global expansion of Labcorp Tissue® Complete, which happens to be a tissue-based comprehensive genomic profiling assay of over 500 genes for pan-solid tumors.
When deployed in conjunction, these assays will facilitate consistent, high-quality testing across regions so to cut down on variability in results and streamline workflows for biopharma partners.
Rounding up highlights would be the introduction of an enhanced digital pathology platform for clinical trials. This particular platform will leverage Leica Biosystems Aperio GT450 scanners and Proscia’s Concentriq LS image management system to offer scalable, file-agnostic infrastructure, and therefore, support scanning, archival, and companion diagnostic development.
Apart from that, the technology further enables real-time global peer review, all while conceiving more accurate, actionable insights, thanks to its ability to integrate high-volume image analysis and leverage AI-driven interpretation.
Founded in 1978, Labcorp’s rise up the ranks stems from its comprehensive and cutting-edge assortment of laboratory services that have made a name for themselves by empowering doctors, hospitals, pharmaceutical companies, researchers, and patients to make confident decisions. The company’s excellence in what it does can also be understood once you consider it provided support for more than 75% of the new drugs and therapeutic products approved during 2024 by the FDA.
Not just that, Labcorp had also performed more than 700 million tests annually for patients around the world.
“Labcorp is committed to serving as the trusted partner for advanced testing at every stage of cancer care,” said Shakti Ramkissoon, M.D., Ph.D., vice president and medical lead for oncology at Labcorp. “Our expanded portfolio and integrated solutions provide our partners with the tools and insights they need to accelerate development programs and drive meaningful improvement in patient outcomes.”
